5 Stocks Raising The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 15,304 as of Thursday, May 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 979 issues advancing vs. 1,985 declining with 110 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is down 0.37. Top gainers within the industry include Forest Laboratories ( FRX), up 3.4%, and Bristol-Myers Squibb Company ( BMY), up 0.5%. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 1.75.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Pharmacyclics Incorporated ( PCYC) is one of the companies pushing the Drugs industry higher today. As of noon trading, Pharmacyclics Incorporated is up $2.13 (2.59) to $84.48 on average volume Thus far, 365,025 shares of Pharmacyclics Incorporated exchanged hands as compared to its average daily volume of 789,500 shares. The stock has ranged in price between $79.51-$85.28 after having opened the day at $81.26 as compared to the previous trading day's close of $82.35.

Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics Incorporated has a market cap of $6.2 billion and is part of the health care sector. The company has a P/E ratio of 73.2, above the S&P 500 P/E ratio of 17.7. Shares are up 46.6% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Pharmacyclics Incorporated a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Pharmacyclics Incorporated as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Pharmacyclics Incorporated Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015